Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06657183 · ClinicalTrials.gov registry record · NA
ECM and Monitoring w/ Alio Smart Patch in Cancer Pts Receiving Chemotherapy
A NA study of Febrile Neutropenia, sponsored by Case Comprehensive Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06657183: Recruiting NA study of Febrile Neutropenia, sponsored by Case Comprehensive Cancer Center.
NCT06657183 is a NA study of Febrile Neutropenia that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06657183, a NA study of Febrile Neutropenia, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Undergoing cancer treatment comes with various risks and side effects. This clinical trial aims to reduce those risks and side effects through continuous monitoring of vital signs and blood levels. The goal is to see if potential side effects can be identified and treated sooner. During this study, participants will wear an Alio Smartpatch™. The Alio Smartpatch™ is a wireless remote monitoring system. This device will measure participants' vital signs and blood levels. Participants will also be asked to use continuous glucose monitors to measure their glucose levels. The data collected on each participant from these devices will be remotely monitored at all times by clinical staff at a company known as Quantify Remote Care. If a participant's results look like they are experiencing a side effect, the participant will be contacted immediately by Quantify Remote Care team. The Quantify Remote Care team will function as an extension of the participant's cancer clinical team and will relay any significant issues back to them. Quantify Health also provides dietary and mental health support as needed for all participants.
Primary Outcome
Rate of participant compliance will be measured. Alio Smartpatch Compliance is defined as \>=80% daily use, reflecting participant adherence to the prescribed monitoring regimen.
Conditions Studied
Interventions
- DEVICE Alio Smart Patch™
Study Locations (1)
Ohio
- Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-08-06 |
| Est. Completion | 2026-10 |
| Phase | NA |
What NCT06657183 shows while recruiting
NCT06657183 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Febrile Neutropenia appearing as the primary indexed condition, and to 1 intervention - of which Alio Smart Patch™ is the first listed.
NCT06657183 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06657183 about?
NCT06657183 is a clinical study titled "ECM and Monitoring w/ Alio Smart Patch in Cancer Pts Receiving Chemotherapy". Undergoing cancer treatment comes with various risks and side effects. This clinical trial aims to reduce those risks and side effects through continuous monitoring of vital signs and blood levels. The goal is to see if potential side effects can be identified and treated sooner. During this study,...
What is the current status of trial NCT06657183?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-08-06. Estimated completion is 2026-10.
What conditions does trial NCT06657183 study?
This clinical trial studies the following conditions: Febrile Neutropenia.
What interventions are being tested in trial NCT06657183?
The interventions under investigation include: Alio Smart Patch™ (DEVICE).
Who is sponsoring clinical trial NCT06657183?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06657183 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Febrile Neutropenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06657183's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI